OncoCyte SG&A Expense (Quarterly) Analysis

OncoCyte Corp (OCX)

2.89 +0.02 (+0.70%) USD | NASDAQ | May 10, 16:00

2.89 0.00 (0.00%) After-Hours: 18:05

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	2.391M
September 30, 2023	3.183M
June 30, 2023	3.855M
March 31, 2023	4.107M
December 31, 2022	4.623M
September 30, 2022	5.549M
June 30, 2022	5.448M
March 31, 2022	5.913M
December 31, 2021	-3.207M
September 30, 2021	8.426M
June 30, 2021	8.284M
March 31, 2021	7.018M
December 31, 2020	5.284M
September 30, 2020	6.563M
June 30, 2020	5.321M
March 31, 2020	6.115M
December 31, 2019	5.205M
September 30, 2019	3.632M
June 30, 2019	3.954M

Date	Value
March 31, 2019	2.654M
December 31, 2018	2.843M
September 30, 2018	1.496M
June 30, 2018	1.904M
March 31, 2018	2.445M
December 31, 2017	2.385M
September 30, 2017	4.999M
June 30, 2017	1.592M
March 31, 2017	2.698M
December 31, 2016	1.663M
September 30, 2016	1.219M
June 30, 2016	1.337M
March 31, 2016	1.243M
December 31, 2015	2.11M
September 30, 2015	1.312M
June 30, 2015	0.519M
March 31, 2015	0.25M
December 31, 2014	0.373M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

-3.207M

Minimum

Dec 2021

8.426M

Maximum

Sep 2021

4.824M

Average

5.284M

Median

Dec 2020

SG&A Expense (Quarterly) Benchmarks